Anti-CD20 (Clone: B9E9)

CD20 is clinically validated as an immunotherapy target for B-cell lymphomas and autoimmune diseases. CD20 consists of large, intracellular, amino- and carboxyterminal portions connected by 4 membrane-spanning domains. Its high expression on malignant B cells and its reported lack of shedding from the surface make CD20 an ideal target for antibody-mediated killing. Anti-CD20 antibodies are believed to mediate the therapeutic effect by activation of complement-dependent cytotoxicity (CDC) and largely by antibody-dependent cellular cytotoxicity exerted by recruitment of innate immune effector cells expressing the Fcgamma receptor IIIa. Protein function: This protein may be involved in the regulation of B-cell activation and proliferation. [The UniProt Consortium]